Futura Medical’s Global Eroxon® Rollout on Track
Company Announcements

Futura Medical’s Global Eroxon® Rollout on Track

Futura Medical (GB:FUM) has released an update.

Futura Medical PLC has successfully launched its flagship sexual health product, Eroxon®, in at least ten countries, including key European markets, with revenues aligning with market expectations for FY2024. The company is optimistic about further launches planned for the second half of the year and projects profitability within the next 12 months. In partnership with global consumer healthcare company Haleon, Futura is also preparing for the US market entry of Eroxon®, anticipated within the year.

For further insights into GB:FUM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskFutura Medical Reveals Promising Product Pipeline Results
TipRanks UK Auto-Generated NewsdeskFutura Medical’s Share Capital and Market Expansion
TipRanks UK Auto-Generated NewsdeskFutura Medical’s Eroxon Shows Promise in ED Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App